参考:
1. Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S (2015). "Therapeutic cancer vaccines". J Clin Invest. 125 (9): 3401–12. doi:10.1172/JCI80009. PMC 4588240 Freely accessible. Archived from the original on 2017-06-29.
2. Bol K, et al. (2016). "Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity". Cancer Immunology, Immunotherapy. 65 (3): 327–39. doi:10.1007/s00262-016-1796-7. PMC 4779136 Freely accessible.
3. Brotherton J (2015). "HPV prophylactic vaccines: lessons learned from 10 years experience". Future Medicine. 10 (8): 999–1009. doi:10.2217/fvl.15.60.
4. Frazier I (2014). "Development and Implementation of Papillomavirus Prophylactic Vaccines". J. Immunol. 192 (9): 4007–11. doi:10.4049/jimmunol.1490012. Archived from the original on 2017-08-11.
5.United States Centers for Disease Control and Prevention (2011). A CDC framework for preventing infectious diseases. Archived 2017-08-29 at the Wayback Machine. Accessed 11 September 2012. "Vaccines are our most effective and cost-saving tools for disease prevention, preventing untold suffering and saving tens of thousands of lives and billions of dollars in healthcare costs each year."
American Medical Association (2000). Vaccines and infectious diseases: putting risk into perspective. Archived 2015-02-05 at the Wayback Machine. Accessed 11 September 2012. "Vaccines are the most effective public health tool ever created."
Public Health Agency of Canada. Vaccine-preventable diseases. Archived 2015-03-13 at the Wayback Machine. Accessed 11 September 2012. "Vaccines still provide the most effective, longest-lasting method of preventing infectious diseases in all age groups."
United States National Institute of Allergy and Infectious Diseases (NIAID). NIAID Biodefense Research Agenda for Category B and C Priority Pathogens. Archived 2016-03-04 at the Wayback Machine. Accessed 11 September 2012. "Vaccines are the most effective method of protecting the public against infectious diseases."
6. Fiore AE, Bridges CB, Cox NJ (2009). "Seasonal influenza vaccines". Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology. 333: 43–82. doi:10.1007/978-3-540-92165-3_3. ISBN 978-3540921646. PMID 19768400.
7. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS (July 2009). "Evaluating the impact of human papillomavirus vaccines". Vaccine. 27 (32): 4355–62. doi:10.1016/j.vaccine.2009.03.008. PMID 19515467.
8. Liesegang TJ (August 2009). "Varicella zoster virus vaccines: effective, but concerns linger". Can. J. Ophthalmol. 44 (4): 379–84. doi:10.3129/i09-126. PMID 19606157.
9. World Health Organization, Global Vaccine Action Plan 2011-2020. Archived 2014-04-14 at the Wayback Machine. Geneva, 2012.
10. Baxby, Derrick (1999). "Edward Jenner's Inquiry; a bicentenary analysis". Vaccine. 17 (4): 301–07. doi:10.1016/s0264-410x(98)00207-2. PMID 9987167.
11. Pasteur, Louis (1881). "Address on the Germ Theory". Lancet. 118 (3024): 271–72. doi:10.1016/s0140-6736(02)35739-8.
12. Grammatikos, Alexandros P.; Mantadakis, Elpis; Falagas, Matthew E. (June 2009). "Meta-analyses on Pediatric Infections and Vaccines". Infectious Disease Clinics of North America. 23 (2): 431–57. doi:10.1016/j.idc.2009.01.008. PMID 19393917.
13. Neighmond, Patti (2010-02-07). "Adapting Vaccines For Our Aging Immune Systems". Morning Edition. NPR. Archived from the original on 2013-12-16. Retrieved 2014-01-09.open access publication – free to read
14. Sullivan, Patricia (2005-04-13). "Maurice R. Hilleman dies; created vaccines". Wash. Post. Archived from the original on 2012-10-20. Retrieved 2014-01-09.open access publication – free to read
15. Schlegel; et al. (August 1999). "Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: cohort study". BMJ. 319 (7206): 352. doi:10.1136/bmj.319.7206.352. PMC 32261 Freely accessible. PMID 10435956. Archived from the original on 2014-01-10. Retrieved 2014-01-09.open access publication – free to read
16. Préziosi, M.; Halloran, M.E. (2003). "Effects of Pertussis Vaccination on Disease: Vaccine Efficacy in Reducing Clinical Severity". Clinical Infectious Diseases. Oxford Journals. 37 (6): 772–79. doi:10.1086/377270.
17. Orenstein WA, Papania MJ, Wharton ME (2004). "Measles elimination in the United States". J Infect Dis. 189 (Suppl 1): S1–3. doi:10.1086/377693. PMID 15106120.
18. "Measles—United States, January 1 – April 25, 2008". Morb. Mortal. Wkly. Rep. 57 (18): 494–98. May 2008. PMID 18463608. Archived from the original on October 11, 2017.open access publication – free to read
19. "WHO South-East Asia Region certified polio-free". WHO. 27 March 2014. Archived from the original on 27 March 2014. Retrieved November 3, 2014.
20. 19 July 2017 Vaccines promoted as key to stamping out drug-resistant microbes "Immunization can stop resistant infections before they get started, say scientists from industry and academia." Archived 22 July 2017 at the Wayback Machine.
21. Maglione, M. A.; Das, L.; Raaen, L.; Smith, A.; Chari, R.; Newberry, S.; Shanman, R.; Perry, T.; Goetz, M. B.; Gidengil, C. (1 July 2014). "Safety of Vaccines Used for Routine Immunization of US Children: A Systematic Review". Pediatrics. 134 (2): 325–37. doi:10.1542/peds.2014-1079. PMID 25086160.
22. "Possible Side-effects from Vaccines". Centers for Disease Control and Prevention. Archived from the original on 17 March 2017. Retrieved 24 February 2014.
23. "Seasonal Flu Shot – Seasonal Influenza (Flu)". CDC. Archived from the original on 2015-10-01.
24. "Vaccine Types". National Institute of Allergy and Infectious Diseases. 2012-04-03. Archived from the original on 2015-09-05. Retrieved 2015-01-27.
25. "Types of Vaccines". Archived from the original on 2017-07-29. Retrieved October 19, 2017.
26. J.K. Sinha; S. Bhattacharya. A Text Book of Immunology (Google Book Preview). Academic Publishers. p. 318. ISBN 978-8189781095. Retrieved 2014-01-09.
27. Kim W, Liau LM (2010). "Dendritic cell vaccines for brain tumors". Neurosurg Clin N Am. 21 (1): 139–57. doi:10.1016/j.nec.2009.09.005. PMC 2810429 Freely accessible. PMID 19944973.
28. Anguille, S; Smits, EL; Lion, E; van Tendeloo, VF; Berneman, ZN (June 2014). "Clinical use of dendritic cells for cancer therapy". The Lancet. Oncology. 15 (7): e257–67. doi:10.1016/s1470-2045(13)70585-0. PMID 24872109.
29. McKenzie, David (26 May 2018). "Fear and failure: How Ebola sparked a global health revolution". CNN. Retrieved 26 May 2018.
30. Meri, S; Jördens, M; Jarva, H (December 2008). "Microbial complement inhibitors as vaccines". Vaccine. 26 Suppl 8: I113–17. doi:10.1016/j.vaccine.2008.11.058. PMID 19388175.
31. "Monovalent" at Dorland's Medical Dictionary
32. Polyvalent vaccine at Dorlands Medical Dictionary Archived March 7, 2012, at the Wayback Machine.
33. "Questions And Answers On Monovalent Oral Polio Vaccine Type 1 (mOPV1)'Issued Jointly By WHO and UNICEF'". Pediatric Oncall. 2 (8). 3. What advantages does mOPV1 have over trivalent oral polio vaccine (tOPV)?. 2005-01-08. Archived from the original on 2012-02-29.
34. Scott (April 2004). "Classifying Vaccines" (PDF). BioProcesses International: 14–23. Archived (PDF) from the original on 2013-12-12. Retrieved 2014-01-09.
35. Centers for Disease Control and Prevention, U.S. Vaccine Names, archived from the original on 2016-05-26, retrieved 2016-05-21.
36. Centers for Disease Control and Prevention, Tetanus (Lockjaw) Vaccination, archived from the original on 2016-05-16, retrieved 2016-05-21.
37. Centers for Disease Control and Prevention, Vaccine Acronyms and Abbreviations [Abbreviations used on U.S. immunization records], archived from the original on 2017-06-02, retrieved 2017-05-22.
38. Sutter RW, Cochi SL, Melnick JL (1999). "Live attenuated polio vaccines". In Plotkin SA, Orenstein WA. Vaccines. Philadelphia: W. B. Saunders. pp. 364–408.
39. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. (2001). "Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers". Vaccine. 19 (23–24): 3179–88. doi:10.1016/S0264-410X(01)00020-2. PMID 11312014.
40. "Institute for Vaccine Safety – Thimerosal Table". Archived from the original on 2005-12-10.
41. Wharton, Melinda E.; National Vaccine Advisory committee "U.S.A. national vaccine plan" Archived 2016-05-04 at the Wayback Machine.
42.http://www.npl.co.uk/environment ... nts/ngp_metals.html Archived 29 September 2007 at the Wayback Machine.
43. "ACIP Vaccine Recommendations Home Page". CDC. 2013-11-15. Archived from the original on 2013-12-31. Retrieved 2014-01-10.
44. "Vaccine Status Table". Red Book Online. American Academy of Pediatrics. April 26, 2011. Archived from the original on December 27, 2013. Retrieved January 9, 2013.
45. "HPV Vaccine Safety". Centers for Disease Control and Prevention (CDC). 2013-12-20. Archived from the original on 2009-11-10. Retrieved 2014-01-10.
46. "HPV vaccine in the clear". NHS choices. 2009-10-02. Archived from the original on 2014-01-10. Retrieved 2014-01-10.open access publication – free to read
47. Needham, Joseph. (2000). Science and Civilization in China: Volume 6, Biology and Biological Technology, Part 6, Medicine. Cambridge: Cambridge University Press. p.154
48. Williams, Gareth (2010). Angel of Death. Basingstoke: Palgrave Macmillan. ISBN 978-0230274716.
49. Silverstein, Arthur M. (2009). A History of Immunology (2nd ed.). Academic Press. p. 293. ISBN 978-0080919461..
50. Stern AM, Markel H (2005). "The history of vaccines and immunization: familiar patterns, new challenges". Health Aff. (Millwood). 24 (3): 611–21. doi:10.1377/hlthaff.24.3.611. PMID 15886151. Archived from the original on 2014-04-24.open access publication – free to read
51. Dunn PM (January 1996). "Dr Edward Jenner (1749–1823) of Berkeley, and vaccination against smallpox" (PDF). Arch. Dis. Child. Fetal Neonatal Ed. 74 (1): F77–78. doi:10.1136/fn.74.1.F77. PMC 2528332 Freely accessible. PMID 8653442. Archived from the original (PDF) on 2011-07-08.
52. Van Sant JE (2008). "The Vaccinators: Smallpox, Medical Knowledge, and the 'Opening' of Japan". J Hist Med Allied Sci. 63 (2): 276–79. doi:10.1093/jhmas/jrn014.
53. Dudgeon JA (1963). "Development of smallpox vaccine in England in the eighteenth and nineteenth centuries". BMJ (5342): 1367–72. doi:10.1136/bmj.1.5342.1367. PMC 2124036 Freely accessible. PMID 20789814.
54. Baarda, Benjamin I.; Sikora, Aleksandra E. (2015). "Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease". Frontiers in Microbiology. 6. doi:10.3389/fmicb.2015.01190. ISSN 1664-302X; Access provided by the University of Pittsburgh.
55. Goodman, Jesse L. (2005-05-04). "Statement by Jesse L. Goodman, M.D., M.P.H. Director Center for Biologics, Evaluation and Research Food and Drug Administration U.S. Department of Health and Human Services on US Influenza Vaccine Supply and Preparations for the Upcoming Influenza Season before Subcommittee on Oversight and Investigations Committee on Energy and Commerce United States House of Representatives". Archived from the original on 2008-09-21. Retrieved 2008-06-15.
56. Olesen OF, Lonnroth A, Mulligan B (2009). "Human vaccine research in the European Union". Vaccine. 27 (5): 640–45. doi:10.1016/j.vaccine.2008.11.064. PMID 19059446.
57. Jit, Mark; Newall, Anthony T.; Beutels, Philippe (1 April 2013). "Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies". Human vaccines & immunotherapeutics. 9 (4): 834–840. doi:10.4161/hv.23637. PMC 3903903 Freely accessible. PMID 23357859.
58. Newall, A.T.; Reyes, J.F.; Wood, J.G.; McIntyre, P.; Menzies, R.; Beutels, P. (February 2014). "Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses". Vaccine. 32 (7): 759–65. doi:10.1016/j.vaccine.2013.11.067. PMID 24295806.
59. Hardman Reis T (2006). "The role of intellectual property in the global challenge for immunization". J World Intellect Prop. 9 (4): 413–25. doi:10.1111/j.1422-2213.2006.00284.x.
60. "www.who.int" (PDF). Archived (PDF) from the original on 2015-11-23.
61. "Three ways to make a vaccine" (infographic). Archived from the original on 2015-12-23. Retrieved 2015-08-05, in Stein, Rob (24 November 2009). "Vaccine system remains antiquated". The Washington Post. Archived from the original on 19 October 2017.
62. Muzumdar JM, Cline RR (2009). "Vaccine supply, demand, and policy: a primer". J Am Pharm Assoc. 49 (4): e87–99. doi:10.1331/JAPhA.2009.09007. PMID 19589753.
63. "Components of a vaccine". Archived from the original on 2017-06-13.
64. Bae K, Choi J, Jang Y, Ahn S, Hur B (2009). "Innovative vaccine production technologies: the evolution and value of vaccine production technologies". Arch Pharm Res. 32 (4): 465–80. doi:10.1007/s12272-009-1400-1. PMID 19407962.
65. Staff (15 November 2011). "India produces 60 percent of world's vaccines". Indonesia. Antara. Archived from the original on 19 September 2015. Retrieved 2015-08-05.
66. CDC. "Ingredients of Vaccines — Fact Sheet". Archived from the original on December 17, 2009. Retrieved December 20, 2009.
67. The mercury levels in the table, unless otherwise indicated, are taken from: Mercury Levels in Commercial Fish and Shellfish (1990-2010) Archived 2015-05-03 at the Wayback Machine. U.S. Food and Drug Administration. Accessed 8 January 2012.
68. "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-09-06. Archived from the original on 2013-01-06. Retrieved 2007-10-01.
69. Bigham M, Copes R (2005). "Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease". Drug Saf. 28 (2): 89–101. doi:10.2165/00002018-200528020-00001. PMID 15691220.
70. Offit PA (2007). "Thimerosal and vaccines—a cautionary tale" (PDF). N Engl J Med. 357 (13): 1278–79. doi:10.1056/NEJMp078187. PMID 17898096. Archived from the original on 2011-09-21.
71. Morein B, Hu KF, Abusugra I (2004). "Current status and potential application of ISCOMs in veterinary medicine". Adv Drug Deliv Rev. 56 (10): 1367–82. doi:10.1016/j.addr.2004.02.004. PMID 15191787.
72. American Medicine. American-Medicine Publishing Company. 1926.
73. South African Institute for Medical Research (1929). Annual report [Jaarverslag]. South African Institute for Medical Research – Suid-Afrikaanse Instituut vir Mediese Navorsing.
74. Firdos Alam Khan (2011-09-20). Biotechnology Fundamentals. CRC Press. p. 270. ISBN 978-1439820094.
75. Giudice EL, Campbell JD (2006). "Needle-free vaccine delivery". Adv Drug Deliv Rev. 58 (1): 68–89. doi:10.1016/j.addr.2005.12.003. PMID 16564111.
76. WHO to trial Nanopatch needle-free delivery system| ABC News, 16 Sep 2014| "Archived copy". Archived from the original on 2015-04-02. Retrieved 2015-09-15.
77. "Australian scientists develop 'needle-free' vaccination". The Sydney Morning Herald. 18 August 2013. Archived from the original on 25 September 2015.
78. Vaxxas raises $25m to take Brisbane's Nanopatch global| Business Review Weekly, 10 February 2015 |"Archived copy". Archived from the original on 2015-03-16. Retrieved 2015-03-05.
79. "Australian scientists develop 'needle-free' vaccination". Chennai, India: The Hindu. 28 September 2011. Archived from the original on 1 January 2014.
80. "Needle-free nanopatch vaccine delivery system". News Medical. 3 August 2011. Archived from the original on 11 May 2012.
81. Lowe (2008). "Plasmid DNA as Prophylactic and Therapeutic vaccines for Cancer and Infectious Diseases". Plasmids: Current Research and Future Trends. Caister Academic Press. ISBN 978-1904455356. Archived from the original on 2008-04-11.
82. Patel, JR; Heldens, JG (March 2009). "Immunoprophylaxis against important virus disease of horses, farm animals and birds". Vaccine. 27 (12): 1797–810. doi:10.1016/j.vaccine.2008.12.063. PMID 19402200.
83. Berkelman, Ruth L. (1 August 2003). "Human Illness Associated with Use of Veterinary Vaccines". Clinical Infectious Diseases. 37 (3): 407–14. doi:10.1086/375595. PMID 12884166.open access publication – free to read
84. Van Oirschot JT, Rziha HJ, Moonen PJ, Pol JM, Van Zaane D (1986). "Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive enzyme immunoassay". The Journal of General Virology. 67 (6): 1179–82. doi:10.1099/0022-1317-67-6-1179. PMID 3011974.
85. Van Oirschot JT (1999). "Diva vaccines that reduce virus transmission". Journal of Biotechnology. 73 (2–3): 195–205. doi:10.1016/S0168-1656(99)00121-2. PMID 10486928.
86. Van Oirschot JT, Gielkens AL, Moormann RJ, Berns AJ (1990). "Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease". Veterinary Microbiology. 23 (1–4): 85–101. doi:10.1016/0378-1135(90)90139-M. PMID 2169682.
87. Van Oirschot JT (1999). "Diva vaccines that reduce virus transmission". Journal of Biotechnology. 73 (2–3): 195–205. doi:10.1016/S0168-1656(99)00121-2. PMID 10486928.
88. Kaashoek MJ, Moerman A, Madic J, Rijsewijk FA, Quak J, Gielkens AL, Van Oirschot JT (1994). "A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine". Vaccine. 12 (5): 439–44. doi:10.1016/0264-410X(94)90122-8. PMID 8023552.
89. Hulst MM, Westra DF, Wensvoort G, Moormann RJ (1993). "Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera". Journal of Virology. 67 (9): 5435–42. PMC 237945 Freely accessible. PMID 8350404.
90. Capua I, Terregino C, Cattoli G, Mutinelli F, RodriguezJF (2003). "Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza". Avian Pathology. 32 (1): 47–55. doi:10.1080/0307945021000070714. PMID 12745380.
91. Maas A, Meens J, Baltes N, Hennig-Pauka I, Gerlach GF (2006). "Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection". Vaccine. 24 (49): 7226–32. doi:10.1016/j.vaccine.2006.06.047. PMID 17027123.
92. Leyman B, Boyen F, Van Parys A, Verbruggh E, Haesebrouck F, Pasmans F (2011). "Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs". Vaccine. 29 (20): 3679–85. doi:10.1016/j.vaccine.2011.03.004. PMID 21419163. Archived from the original on 2017-10-28.
93. Plotkin SA (2005). "Vaccines: past, present and future". Nat Med. 11 (4 Suppl): S5–11. doi:10.1038/nm1209. PMID 15812490.
94. Carlson B (2008). "Adults now drive growth of vaccine market". Gen. Eng. Biotechnol. News. 28 (11). pp. 22–3. Archived from the original on 2014-01-10.open access publication – free to read
95. Klein SL, Jedlicka A, Pekosz A (May 2010). "The Xs and Y of immune responses to viral vaccines". Lancet Infect Dis. 10 (5): 338–49. doi:10.1016/S1473-3099(10)70049-9. PMID 20417416.
96. Staff (28 March 2013). "Safer vaccine created without virus". The Japan Times. Agence France-Presse – Jiji Press. Archived from the original on 30 March 2013. Retrieved 2013-03-28.
97. Spohn G, Bachmann MF (2008). "Exploiting viral properties for the rational design of modern vaccines". Expert Rev Vaccines. 7 (1): 43–54. doi:10.1586/14760584.7.1.43. PMID 18251693.
98. Samuelsson O, Herlitz H (2008). "Vaccination against high blood pressure: a new strategy". Lancet. 371 (9615): 788–89. doi:10.1016/S0140-6736(08)60355-4. PMID 18328909.
99. Poland GA, Jacobson RM, Ovsyannikova IG (2009). "Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics". Vaccine. 27 (25–26): 3240–44. doi:10.1016/j.vaccine.2009.01.069. PMC 2693340 Freely accessible. PMID 19200833.
100. Sala, F.; Manuela Rigano, M.; Barbante, A.; Basso, B.; Walmsley, AM; Castiglione, S (January 2003). "Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives". Vaccine. 21 (7–8): 803–08. doi:10.1016/s0264-410x(02)00603-5. PMID 12531364.
101. Kumar, G. B. Sunil; T. R. Ganapathi; C. J. Revathi; L. Srinivas; V. A. Bapat (October 2005). "Expression of hepatitis B surface antigen in transgenic banana plants". Planta. 222 (3): 484–93. doi:10.1007/s00425-005-1556-y. PMID 15918027.
102. Ostachuk A; Chiavenna SM; Gómez C; Pecora A; Pérez-Filgueira MD; Escribano JA; Ardila F; Dus Santos MJ; Wigdorovitz A (2009). "Expression of a ScFv–E2T fusion protein in CHO-K1 cells and alfalfa transgenic plants for the selective directioning to antigen presenting cells". Veterinary Immunology and Immunopathology. 128 (1): 315. doi:10.1016/j.vetimm.2008.10.224. Archived from the original on 2018-05-01.
103. Aguirreburualde MSP; Gómez C; Ostachuk A; Wolman F; Albanesi G; Pecora A; Odeon A; Ardila F; Escribano JA; Dus Santos MJ; Wigdorovitz A (2013). "Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants". Veterinary Immunology and Immunopathology. 151 (3): 315–324. doi:10.1016/j.vetimm.2012.12.004. Archived from the original on 2018-05-01.